| Drug Name | Company or Sponsor | Essential Thrombocythemia ET/ Polycythemia Vera PV | Clinical Trial (click ID# for link to trial information) | Phase | Site Locations / More Info |
|---|---|---|---|---|---|
| Ropeginterferon/BESREMI | PharmaEssentia | PV | NCT04182100 APPROVED | click here for more info | |
| NCT04285086 | PharmaEssentia | ET | NCT04285086 open, not recruiting | 3 | Click here for trial info |
| Bomedemstat/IMG-7289 | Imago BioSciences | ET | NCT04254978 completed | 2 | click here for trial info |
| Rusfertide | Protagonist Therapeutics, Inc. | PV | NCT05210790 open, recruiting | 3 | click here for more trial info |
| NCT03194542 | Celgene | NCT03194542 completed | Click here for trial info | ||
| NCT03755518 | Celgene | NCT03755518 completed | Click here for trial info | ||
| Ruxolitinib | Novartis | NCT02386800 open, recruiting | 4-roll over protocol | click here for more trial info | |
| Ruxolitinib | Incyte Corp Novartis | Yes | NCT01317875 completed | Completed | click here for more trial info |
| P1101 | PharmaEssentia | ET | NCT05482971 open, recruiting | 2 | click here for more trial info |
| P1101 | PharmaEssentia | PV | NCT05481151 open, recruiting | 3 | click here for more trial info |
| LCL-161 | Novartis | NCT02098161 enrollment complete | Completed | Click here for more trial info | |
| PTG-300 | Protagonist Therapeutics, Inc. | NCT04057040 active, not recruiting | 2 | Click here for more trial info | |
| Pacritinib | CTI BioPharma | NCT03165734 open, recruiting | 2 | Click here for more trial info | |
| Sapablursen | Ionis Pharmaceuticals, Inc. | PV | NCT05143957 open, recruiting | 2 | Click here for trial info |
| Observational Study | Incyte | NCT2953704 enrollment complete | Completed | Click here for more trial info | |
| Anagrelide and Hydroxyurea for PV | Incyte Corp. | No | NCT02252159 enrollment complete | Observational Study/ Completed | click here for trial info |
| Mirabegron | Swiss Group for Clinical Cancer Research | NCT02311569 enrollment complete | Completed | click here for trial info | |
| NS-018 | NS Pharma | No | NCT01423851 enrollment complete | Completed | click here for trial info |
| P1101 Pegylated-Proline-interferon alpha-2b | PharmaEssentia AOP Orphan Pharmaceuticals | NCT02218047 enrollment complete | 3 | Click here for more information | |
| Ruxolitinib | Novartis | NCT02577926 open, not recruiting | 2 | click here for trial info | |
| Momelotinib | Gilead Sciences | NCT02101268 enrollment complete | 3 | click here for trial info | |
| PRM-151 | Promedior | NCT01981850 enrollment complete | 2 | Click here for location and trial info | |
| Navtemadlin (KRT-232) | Kartos | No | NCT03669965 unknown status | 2 | click here for trial info |
| NCT03069326 | Incyte | NCT03069326 open, not recruiting | 2 | Click here for trial info | |
| Fedratinib, Ivosidenib, Enasidenib | Bristol Myers Squibb (BMS), Servier | ET/PV | NCT04955938 open, recruiting | 1/2 | Click here for trial info |
| SLN124 | Silence Therapeutics | PV | NCT05499013 open, recruiting | 1/2 | Click here for trial info |
| VAC85135 Ipilimumab | Janssen Research & Development, LLC | ET/PV | NCT05444530 open, recruiting | 1 | Click here for trial info |
